V Square Quantitative Management LLC Sells 3,774 Shares of AbbVie Inc. $ABBV

V Square Quantitative Management LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 34.1% in the 4th quarter, HoldingsChannel reports. The fund owned 7,293 shares of the company’s stock after selling 3,774 shares during the period. V Square Quantitative Management LLC’s holdings in AbbVie were worth $1,666,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Diversified Trust Co boosted its holdings in shares of AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares during the last quarter. Permanent Capital Management LP purchased a new stake in shares of AbbVie in the 3rd quarter valued at $720,000. Railway Pension Investments Ltd boosted its holdings in shares of AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the last quarter. World Investment Advisors boosted its holdings in shares of AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co boosted its holdings in shares of AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock valued at $7,434,000 after acquiring an additional 15,502 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of several recent research reports. Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Evercore lowered their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Cantor Fitzgerald lowered their price target on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $252.65.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued the U.S. government seeking a narrower definition of which patients qualify for a federal drug-discount program — a move investors see as an attempt to limit mandated discounts and protect revenue/margins. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data for Skyrizi and Rinvoq showcased durability, safety and label expansions that support AbbVie’s immunology growth thesis and revenue visibility. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst and dividend-focused coverage highlights ABBV’s strong cash flow and reliable dividend (Dividend Aristocrat status and recent raises), supporting investor demand for income exposure. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation (AbbVie section)
• Neutral Sentiment: Healthcare sector momentum and “trending” stock mentions (Zacks/coverage pieces) are increasing visibility and trading interest in ABBV, which can amplify moves but are not fundamental catalysts by themselves. AbbVie Inc. (ABBV) Is a Trending Stock
• Neutral Sentiment: Brand/marketing activity — Allergan Aesthetics (BOTOX® Cosmetic) programs and new AMI training center openings — support long-term aesthetics revenue but are incremental near-term. BOTOX® Cosmetic Empowers Women Entrepreneurs
• Negative Sentiment: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie, suggesting AbbVie pulled back promotional share — a potential headwind to maintaining market momentum against competitors. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: AbbVie placed Humira on the TrumpRx platform at a steep discount — a tactical move to maintain access/share that pressures pricing and could weigh on legacy-revenue mix. AbbVie Puts Humira on TrumpRx at Steep Discount
• Negative Sentiment: Some analysts are flagging valuation and competitive concerns; Cantor Fitzgerald trimmed its price target modestly (still overweight), reflecting mixed views on upside vs. risks. Cantor Fitzgerald price target revision note

AbbVie Stock Performance

NYSE:ABBV opened at $211.74 on Thursday. The company has a fifty day moving average of $220.80 and a two-hundred day moving average of $224.19. The stock has a market capitalization of $374.40 billion, a PE ratio of 89.72, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.